Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 34OTHER 18NIH 4NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 4Thoracic 2Plasma cell 2CNS 2Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Adenocarcinoma of Lung 1

Interventions

Cisplatin 40Carboplatin 40Paclitaxel 34Radiotherapy 32Docetaxel 19Pemetrexed 17Gemcitabine 17Etoposide 17Bevacizumab 11Radiosurgery 9Magnetic Resonance Spectroscopy 9Ramucirumab 8durvalumab 7Taxes 7Cetuximab 7pembrolizumab 6Specimen Handling 6Erlotinib Hydrochloride 6Irinotecan 5Gene Expression Profiling 5Filgrastim 5cediranib 4Vinorelbine 4Polymerase Chain Reaction 4Neoadjuvant Therapy 4Fluorodeoxyglucose F18 4Chemotherapy, Adjuvant 4Amplified Fragment Length Polymorphism Analysis 4tremelimumab 3osimertinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Crizotinib × Thoracic × Clear all
NCT02201992 2025-12-19

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

Eastern Cooperative Oncology Group

Phase 3 Active not recruiting
166 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02134912 2020-02-20

S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib

SWOG Cancer Research Network

Phase 2 Terminated
1 enrolled
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡